Postgraduate Program in Dental Sciences, Department of Dentistry, Federal University of Rio Grande do Norte, Av. Salgado Filho, 1787, Lagoa Nova, Natal, RN, CEP: 59056-000, Brazil.
Clin Oral Investig. 2021 Apr;25(4):1767-1774. doi: 10.1007/s00784-020-03479-y. Epub 2020 Aug 4.
To investigate the efficacy of sclerotherapy with monoethanolamine oleate (MEO) in a series of cases of benign oral vascular lesions (BOVL).
Clinical records and images were retrieved (2015-2019), and data regarding age, gender, location, size, symptomatology, treatment and outcomes of patients were collected. All patients were diagnosed according to the classification of International Society for the Study of Vascular Anomalies and received the same treatment protocol (MEO 0.05 g/mL). The collected data were submitted to descriptive analysis and Pearson's chi-square test (p ≤ 0.05).
Thirty-seven patients were treated. Most were female (70.3%) aged 9 to 88 years (median, 57.5 ± 17.4 years). Lower lip (54.1%) was the most affected site followed by buccal mucosa (16.2%). Thirty-two lesions were asymptomatic and 35.1% showed ≤ 0.5 cm in size. In 48.6% of the patients, only one application of MEO was performed. Complete regression occurred in 62.2% of cases, whereas 27% showed partial regression. One patient showed hypersensitivity during treatment. There was no significant difference between clinical outcome and age, anatomic site, size, and number of applications of MEO.
Sclerotherapy with MEO is an acceptable and affordable treatment and can provide satisfactory results in BOVL, especially where other treatment options could compromise the esthetic aspects.
As it is a non-invasive therapy leading, in most cases, to adequate clinical results, safety, and tolerability, sclerotherapy with MEO can be considered an effective treatment for BOVL.
研究单乙醇胺油酸酯（MEO）硬化疗法治疗一系列良性口腔血管病变（BOVL）的疗效。
检索了临床记录和图像（2015-2019 年），并收集了有关患者年龄、性别、部位、大小、症状、治疗和结果的数据。所有患者均根据国际血管异常研究学会的分类进行诊断，并接受相同的治疗方案（MEO 0.05g/ml）。所收集的数据进行描述性分析和皮尔逊卡方检验（p≤0.05）。
共治疗了 37 例患者。大多数患者为女性（70.3%），年龄 9 至 88 岁（中位数，57.5±17.4 岁）。下唇（54.1%）是最常受累的部位，其次是颊黏膜（16.2%）。32 个病变无症状，大小≤0.5cm 的占 35.1%。48.6%的患者仅接受了一次 MEO 治疗。62.2%的病例完全消退，27%的病例部分消退。1 例患者在治疗过程中出现过敏反应。临床疗效与年龄、解剖部位、大小和 MEO 应用次数之间无显著差异。
MEO 硬化疗法是一种可接受且经济实惠的治疗方法，可在 BOVL 中提供满意的结果，特别是在其他治疗方法可能影响美观的情况下。
由于它是一种非侵入性治疗方法，在大多数情况下可获得足够的临床效果、安全性和耐受性，因此 MEO 硬化疗法可被视为治疗 BOVL 的有效方法。
